| Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care |
90 |
| First Human Imaging Studies with the EXPLORER Total-Body PET Scanner |
78 |
| Ga-68-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer |
76 |
| Performance Characteristics of the Digital Biograph Vision PET/CT System |
61 |
| Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT |
56 |
| The Impact of Ga-68-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study |
52 |
| Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein |
51 |
| Ga-68-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers |
50 |
| A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts |
47 |
| Detection Efficacy of F-18-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy |
44 |
| Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control |
40 |
| Ga-68-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning |
39 |
| Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors |
36 |
| Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI |
35 |
| A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET |
35 |
| Efficacy and Safety of High-Specific-Activity I-131-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma |
34 |
| Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes |
34 |
| Metaanalysis of Ga-68-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology |
33 |
| F-18-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma |
31 |
| First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-89-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer |
30 |
| Synthesis and Biologic Evaluation of a Novel F-18-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression |
29 |
| Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms |
29 |
| Performance Evaluation of the Vereos PET/CT System According to the NEMA NU2-2012 Standard |
28 |
| Intraindividual Comparison of F-18-PSMA-1007 and F-18-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study |
28 |
| In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-18-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls |
26 |
| Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC |
26 |
| Early Phase I Study of a Tc-99m-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer |
26 |
| F-18-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor |
25 |
| Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-68-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade |
25 |
| Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0 |
25 |
| PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer |
24 |
| Improving the Accuracy of Simultaneously Reconstructed Activity and Attenuation Maps Using Deep Learning |
23 |
| Immunohistochemical Validation of PSMA Expression Measured by Ga-68-PSMA PET/CT in Primary Prostate Cancer |
22 |
| An Overview of PET Radiochemistry, Part 2: Radiometals |
22 |
| Ga-68-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging |
22 |
| Regional, Artery-Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated with Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease |
21 |
| Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine |
21 |
| Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using Ga-68-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden |
20 |
| Dixon-VIBE Deep Learning (DIVIDE) Pseudo-CT Synthesis for Pelvis PET/MR Attenuation Correction |
19 |
| Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a Ga-68-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04 |
18 |
| RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0 |
18 |
| Cu-64-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy |
18 |
| Clinical Outcomes of Lu-177-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy |
18 |
| Performance of Ga-68-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis |
18 |
| Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-89-Trastuzumab in Patients with Esophagogastric Cancer |
17 |
| Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention |
17 |
| Prospective Evaluation of Ga-68-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging |
17 |
| Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden |
17 |
| PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with Zr-89-Oxine |
17 |
| A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies |
17 |
